Every Claim We Publish, and Where It Came From

This is the fourth temporary extension. Each of the previous three was issued close to its expiry date, so the position may change late in 2026.

No final rule and no withdrawal notice has been published. A rule can also be shelved without a formal withdrawal, so this should not be read as a statement that the DEA intends to finalise it.

Federal DEA telemedicine flexibilities run separately and expire at the end of 2026, and they require video — audio-only does not qualify for ketamine. Spravato cannot be prescribed for home use in any case.

A newer revision of the list may exist that we could not retrieve. Note that Spravato carries only a prior-approval flag — despite what some summaries say, the published list applies no specialty-pharmacy or Spravato-specific quantity flag.

A companion oral antidepressant is required only for the suicidality pathway, not for treatment-resistant depression — which matches the FDA's monotherapy approval. Nevada's criteria do not separately require a REMS-certified site, though the federal REMS rules apply regardless.

The programme covers the medicine, not the office visit or the two-hour observation, which is often the larger share of the bill. The official terms state that a yearly maximum applies but do not publish the amount, so we do not either. Terms are set per calendar year.

Wholesale acquisition cost is published only in paywalled pricing compendia. The figures here are seven years old and come from a secondary source, so we do not use them to produce a dollar estimate — the estimator suppresses Spravato cash figures rather than presenting a number this weak.

Deductible and premium amounts are set annually and change each January.

This is a national policy, so it reads the same wherever you live — which is why it is recorded once here rather than repeated in each state. UnitedHealthcare runs parallel medical and pharmacy versions; which one applies depends on how your clinic bills, and prior approval is needed either way.

This describes one commercial insurer. It does not describe any state Medicaid programme, none of which publishes criteria for racemic ketamine either way.

Anthem's only published criteria date from December 2023 and still require a companion oral antidepressant, which predates the FDA's monotherapy approval — we do not present that requirement as current. Hometown Health publishes no esketamine policy we could find, so we make no claim about it.

Based on three Nevada clinics across both metro areas. Some clinics offer reduced rates for veterans and first responders — worth asking.

We would rather tell you we do not know than repeat a figure we cannot trace to a Nevada clinic.

This is a national company charging the same price everywhere, not a Nevada market rate. It is sold only as a package — a single session is not purchasable at the per-session figure.

Our estimator does not produce a self-pay Spravato figure, because there is no Nevada evidence strong enough to build one on.

Esketamine has no separate DEA listing; it is covered as an enantiomer of ketamine, and the Spravato label carries the CIII designation.

This applies to the treatment-resistant depression indication only. The separate indication for major depressive disorder with acute suicidal ideation still requires an oral antidepressant — see spravato.approval_mdd_si. Widely-cited secondary sources give 21 January 2025; that is the manufacturer's announcement date, not the FDA action date on the approval letter.

The label lists a different set for the major-depressive-disorder-with-acute-suicidality indication. The two lists should not be conflated.

This is a narrative review, not a systematic review, and it reports mixed clinical findings. It does not support any personal recovery timeline.

Commercial payers and state Medicaid programmes each publish their own prior-authorisation wording; the clinical definition and the coverage definition are not always identical.

Trial populations are selected, monitoring is intensive, and individual response cannot be predicted from group averages.

This is research evidence, not an FDA approval. Off-label use remains lawful medical practice when a licensed clinician judges it appropriate.

Do not read this as a treatment recommendation. A bipolar diagnosis changes the assessment and the risk profile; only a treating clinician can decide.

The Spravato label focuses on dissociation, sedation, abuse potential and suicidal thoughts rather than a dedicated mania-switch section; the clinical risk is also described in the bipolar-depression literature cited on this page.

Most cystitis case series describe chronic recreational exposure, not a standard six-infusion clinic course. Absence of a published clinic-dose incidence figure is not proof of zero risk.

Schedule status describes abuse potential relative to other controlled drugs; it is not a prediction that a monitored clinic course will produce dependence.

Employers, courts and sports bodies may order expanded panels. If a drug test is pending, disclose prescribed treatment to the medical review officer rather than relying on a generalisation.

Spravato cannot be taken at home under the REMS. Compounded at-home racemic products are a different regulatory pathway and are not REMS-certified substitutes.

The osteopathic board publishes no public licence lookup that we could verify. To check a DO's licence, contact the Nevada State Board of Osteopathic Medicine directly on 702-732-2147.

Nevada's two-year or 2,000-hour experience threshold applies to Schedule II prescribing only. Ketamine is Schedule III, so that threshold does not affect it.

Whether Nevada hospitals may employ physicians is genuinely unsettled. A 2010 attorney general opinion found no express prohibition, and a 2023 bill to codify one was passed by the legislature and vetoed.

Many summaries say Schedules II to IV. The current statute says II to V.

No Nevada board guidance or court decision resolves the in-clinic administration question, so we do not present either answer as settled.